3 results
Approved WMOCompleted
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
Approved WMOPending
Primary Objective:To evaluate the duration of clinical response of ruxolitinib cream in participants with vitiligo.
Approved WMOCompleted
To establish the clinical and cost-effectiveness of antibiotic-corticosteroid eardrops as compared with oral antibiotics in children with AOMd.